First-in-human phase I study of givastomig, a novel Claudin 18.2/4-1BB bispecific antibody in advanced solid tumors

被引：1

作者：

Ku, G. ^{[1
]}

Shen, L. ^{[2
]}

Klempner, S. J. ^{[3
]}

Pan, H. ^{[4
]}

Kratz, J. ^{[5
]}

Liang, X. ^{[6
]}

Deng, Y. ^{[7
]}

Kim, S. ^{[8
]}

Wang, Z. ^{[9
]}

Feller, L. ^{[10
]}

Powderly, J. ^{[11
]}

Dayyani, F. ^{[12
]}

Schneider, R. E. ^{[13
]}

Girda, E. ^{[14
]}

Berlin, J. D. ^{[15
]}

Spencer, K. ^{[16
]}

Nguyen, M. T. ^{[17
]}

Wang, V. ^{[17
]}

Xu, C. ^{[17
]}

Zhu, A. ^{[18
]}

机构：

[1] MSKCC Mem Sloan Kettering Canc Ctr, Dept Med, Gastrointestinal Oncol Serv, New York, NY USA

[2] Peking Univ Canc Hosp & Inst, GI Oncol Dept, Beijing, Peoples R China

[3] MGH Massachusetts Gen Hosp, Med Oncol Dept, Boston, MA USA

[4] Zhejiang Univ, Sir Run Run Run Shaw Hosp, Med, Sch Med, Hangzhou, Zhejiang, Peoples R China

[5] Univ Wisconsin, Med, Sch Med & Publ Hlth Med Phys, Madison, WI USA

[6] HuBei Canc Hosp, Med Dept, Wuhan, Peoples R China

[7] Sun Yat Sen Univ, Affiliated Hosp 6, Med, Guangzhou, Guangdong, Peoples R China

[8] Univ Colorado, Med Oncol Dept, UCHlth Canc Care, Ctr Canc, Anschutz Med Campus, Aurora, CO USA

[9] China Med Univ, Med, Affiliated Hosp 1, Shenyang, Peoples R China

[10] Horizon BioAdvance, Med Oncol Dept, Lafayette, LA USA

[11] Carolina BioOncol Inst, Oncol, Huntersville, NC USA

[12] UCI Univ Calif Irvine, Med Dept, Hlth Manchester Pavil, Orange, CA USA

[13] Mary Crowley Canc Res Ctr, Med Oncol Dept, Dallas, TX USA

[14] Rutgers Canc Inst New Jersey, Med Oncol Dept, New Brunswick, NJ USA

[15] Vanderbilt Univ, Med Dept, Med Ctr, Preston Canc Res Bldg, Nashville, TN USA

[16] NYU, Med Dept, Langone Laura & Isaac Perlmutter Canc Ctr, New York, NY USA

[17] I Mab Biopharma, Res & Dev, San Diego, CA USA

[18] I Mab Biopharma Co Ltd Headquarter, Res & Dev, Shanghai, Peoples R China

来源：

ANNALS OF ONCOLOGY | 2023年 / 34卷

关键词：

D O I：

10.1016/j.annonc.2023.09.2178

中图分类号：

R73 [肿瘤学];

学科分类号：

100214 ;

摘要：

1039P

引用

页码：S631 / S631

页数：1

共 50 条

[41] Phase I, first-in-human study of futibatinib, a highly selective, irreversible FGFR1-4 inhibitor in patients with advanced solid tumors
Bahleda, R.
Meric-Bernstam, F.
Goyal, L.
Tran, B.
He, Y.
Yamamiya, I
Benhadji, K. A.
Matos, I
Arkenau, H-T
ANNALS OF ONCOLOGY, 2020, 31 (10) : 1405 - 1412
[42] A First-in-Human Phase I Monotherapy Study of RG7212 (R), a Novel Monoclonal Antibody Targeting TWEAK Signaling in Patients with Advanced Solid Tumors
Lassen, U.
Schellens, J. H. M.
Siu, L. L.
Jonker, D. J.
Sorensen, M.
Jarutat, T.
Wang, K.
Gehoe, D.
DeMario, M.
Goss, G.
EUROPEAN JOURNAL OF CANCER, 2012, 48 : 12 - 12
[43] A phase 1, dose escalation/dose-expansion study of QLF31907, a bispecific antibody (BsAb) targeting PD-L1 and 4-1BB, in patients with advanced solid tumors and lymphoma
Lin, Tongyu
Liu, Bin
Pu, Xingxiang
Wu, Lin
Du, Xiaobo
Mo, Ning
Song, Zhengbo
Zhou, Liwei
Duan, Xianlin
Zhu, Yanan
Kang, Xiaoyan
JOURNAL OF CLINICAL ONCOLOGY, 2024, 42 (16)
[44] First-in-human phase 1 study of IT1208, a defucosylated humanized anti-CD4 depleting antibody, in patients with advanced solid tumors
Shitara, Kohei
Uehai, Satoshi
Shichino, Shigeyuki
Aoki, Hiroyasu
Ogiwara, Haru
Nakatsura, Tetsuya
Suzuki, Toshihiro
Shimomura, Manami
Yoshikawa, Toshiaki
Shoda, Kayoko
Kitano, Shigehisa
Yamashita, Makiko
Nakayama, Takayuki
Sato, Akihiro
Kuroda, Sakiko
Wakabayashi, Masashi
Nomura, Shogo
Yokochi, Shoji
Ito, Satoru
Matsushima, Kouji
Doi, Toshihiko
JOURNAL FOR IMMUNOTHERAPY OF CANCER, 2019, 7 : 195
[45] A First-in-Human Phase I Study of INVAC-1, an Optimized Human Telomerase DNA Vaccine in Patients with Advanced Solid Tumors
Teixeira, Luis
Medioni, Jacques
Garibal, Julie
Adotevi, Olivier
Doucet, Ludovic
Durey, Marie-Agnes Dragon
Ghrieb, Zineb
Kiladjian, Jean-Jacques
Brizard, Mara
Laheurte, Caroline
Wehbe, Maria
Pliquet, Elodie
Escande, Marie
Defrance, Remy
Culine, Stephane
Oudard, Stephane
Wain-Hobson, Simon
Doppler, Valerie
Huet, Thierry
Langlade-Demoyen, Pierre
CLINICAL CANCER RESEARCH, 2020, 26 (03) : 588 - 597
[46] First-in-human dose escalation and expansion study of SYSA1801, an antibody-drug conjugate targeting claudin 18.2 in patients with resistant/refractory solid tumors
Wang, Yakun
Gong, Jifang
Lin, Rongbo
Zhao, Shen
Wang, Jufeng
Wang, Qianli
Zhang, Yanqiao
Su, Dan
Zhang, Jingdong
Dong, Qian
Lin, Ling
Tian, Wen
Chen, Ying
Yang, Yang
Zhang, Xueyuan
Wan, Xuechao
Gao, Jinfeng
An, Na
Jansen, Valerie Malyvanh
Shen, Lin
JOURNAL OF CLINICAL ONCOLOGY, 2023, 41 (16)
[47] A phase Ia first-in-human study of JS']JS007, a novel anti-CTLA-4 monoclonal antibody, in patients with advanced solid tumors
Zhang, J.
Zhou, C.
Jiang, J.
Liu, H.
Xiang, X.
Wu, G.
Zeng, R.
Kuang, S.
ANNALS OF ONCOLOGY, 2023, 34 : S633 - S633
[48] First-in-human phase I study of the ALK inhibitor LDK378 in advanced solid tumors.
Mehra, Ranee
Camidge, D. Ross
Sharma, Sunil
Felip, Enriqueta
Tan, Daniel Shao-Weng
Vansteenkiste, Johan F.
De Pas, Tommaso Martino
Kim, Dong-Wan
Santoro, Armando
Liu, Geoffrey
Goldwasser, Meredith
Dai, David
Radona, Marietta
Boral, Anthony
Shaw, Alice Tsang
JOURNAL OF CLINICAL ONCOLOGY, 2012, 30 (15)
[49] First-in-human phase 1 study of DS-1062a in patients with advanced solid tumors.
Sands, Jacob M.
Shimizu, Toshio
Garon, Edward B.
Greenberg, Jonathan
Guevara, Ferdinand M.
Heist, Rebecca Suk
Kobayashi, Fumiaki
Noguchi, Yutaka
Okajima, Daisuke
Tajima, Naoyuki
Spira, Alexander I.
Yamamoto, Noboru
Lisberg, Aaron Elliott
JOURNAL OF CLINICAL ONCOLOGY, 2019, 37 (15)
[50] A phase I first-in-human study of PRI-724 in patients (pts) with advanced solid tumors.
El-Khoueiry, Anthony B.
Ning, Yan
Yang, Dongyun
Cole, Sarah
Kahn, Michael
Zoghbi, Marwan
Berg, Jennifer
Fujimori, Masamoto
Inada, Tetsuhi
Kouji, Hiroyuki
Lenz, Heinz-Josef
JOURNAL OF CLINICAL ONCOLOGY, 2013, 31 (15)

← 1 2 3 4 5 →